Prof. (Dr.) Raj K Shirumalla

Name: Prof. (Dr.) Raj K Shirumalla
Punch Line: Committed to Research to address high unmet medical needs in the area of Cancer and Chronic Inflammatory diseases
Designation: Professor and Director Research
Mobile Number 8595960330
Educational Qualification: Program Year of Passing Board /University
Bachelors B. Pharm 1993 Jamia Hamdard
Masters (Specialization) M. Pharm (Pharmacology) 1995 Jamia Hamdard
Doctorate (Specialization) Ph.D. (Pharmacology) 2009 BITS, Pilani
Any Other Certificate course on Managing Pharmaceutical Development Projects 2004 Pharmaceutical Education and Research Institute, USA.
Work Experience: (in Years)
Total 24 Years
Academics 3 Years
Industry 21 Years
Research 24 Years
Any Other
Recognition and awards
Membership of Associations: Life member of Indian Pharmacological Society and Indian Immunology Society
Registered Pharmacist with Delhi Pharmacy Counc
Awards & recognitions:

Team of the year for 2013 – Daiichi Sankyo India Pharma Pvt. Ltd.

Editor of any Scientific Journal/ member of editorial board
Fund received/ Grant received: Award of Grant from BIRAC under the SIBRI program
Any Other


Ph D: 1
No of papers published:
International: 12
Patents 30
Posters in national and international conferences    10
Any Other
No.: Attended
Conferences: ACR/ARHP Annual Meeting in 2003 in Orlando and 2011 in Philadelphia; American Thoracic Society 2013 International Conference, May 17-22, 2013 – Philadelphia; The ERS International Congress 2016, in London: the world’s largest respiratory meeting. Also attended IPS annual conference in 1995, 1999, 2008, 2010
Guest Lectures Delivered: 5
Resorece Person /Chairperson in a session:
Event(s) organized by department: Organised 1 international conference on Respiratory diseases
Any Other
Any Other Information I am an achievement driven, drug discovery research professional working to address high unmet medical needs. Triaging compounds from early discovery to clinical development has been my forte. My research interest include respiratory diseases, chronic inflammatory diseases and oncology. Currently, I am working on novel first-in-class target to address resistant cancers using chemosensitizers. Also looking to address extracellular matrix degradation in respiratory diseases and to decelerate their progression